• NatureSynthetic


Our Abpromise guarantee covers the use of ab38771 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • FormLiquid
  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General Info

  • Alternative names
    • EC
    • HL 60 PAD
    • HL-60 PAD
    • PAD
    • PAD 4
    • PADI 4
    • PADI 5
    • PADI H protein
    • Padi4
    • PADI5
    • PDI 4
    • PDI 5
    • PDI4
    • PDI5
    • Peptidyl arginine deiminase type IV
    • Peptidyl arginine deiminase type V
    • Peptidylarginine deiminase IV
    • Protein arginine deiminase
    • Protein arginine deiminase type 4
    • Protein arginine deiminase type IV
    • Protein-arginine deiminase type IV
    • Protein-arginine deiminase type-4
    see all
  • FunctionCatalyzes the citrullination/deimination of arginine residues of proteins. Citrullinates histone H3 at 'Arg-8' and/or 'Arg-17' and histone H4 at 'Arg-3', which prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1.
  • Tissue specificityExpressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes.
  • Involvement in diseaseGenetic variations in PADI4 are a cause of susceptibility to rheumatoid arthritis (RA) [MIM:180300]. It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Note=Could have an important role in the pathogenesis of rheumatoid arthritis by increasing citrullination of proteins in rheumatoid arthritis synovial tissues, leading, in a cytokine-rich milieu, to a break in tolerance to citrullinated peptides processed and presented in the appropriate HLA context.
  • Sequence similaritiesBelongs to the protein arginine deiminase family.
  • Cellular localizationCytoplasm. Nucleus. Cytoplasmic granule. Cytoplasmic granules of eosinophils and neutrophils.
  • Information by UniProt

References for Human PADI4 / PAD4 peptide (ab38771)

ab38771 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab38771.
Please use the links above to contact us or submit feedback about this product.